COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00483743
Recruitment Status : Completed
First Posted : June 7, 2007
Last Update Posted : December 3, 2012
Information provided by (Responsible Party):

Brief Summary:
This study will assess and compare the safety and tolerability of inhaled TPI 1020 (repeated nominal doses; 500 μg BID x 6 weeks) versus inhaled budesonide (repeated doses; 800 μg BID x 6 weeks) and a matching placebo. Pharmacodynamic (PD) activity on FEV1, sputum and blood cells and cytokines will also be studied.

Condition or disease Intervention/treatment Phase
Copd Bronchitis Drug: TPI 1020 Drug: Budesonide Drug: Placebo Phase 2

Detailed Description:
A multi-centre, randomized, placebo and active-controlled, 6-week study of inhaled TPI 1020, inhaled budesonide or matching placebo (random allocation of eligible patients to the three treatments at a ratio of 3:3:1), to evaluate the safety, tolerability and pharmacodynamic activity of TPI 1020 in 42 evaluable COPD subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.
Study Start Date : November 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acute Bronchitis
Drug Information available for: Budesonide

Arm Intervention/treatment
Experimental: TPI 1020
TPI 1020 500 mcg BID x 42 days
Drug: TPI 1020
250 mcg/caps 2 caps BID x 42 days

Active Comparator: Budosenide cortico
Budesonide 800 mcg BID x 42 days
Drug: Budesonide
400mcg mcg capsules- 2 capsules BID

Placebo Comparator: Placebo
Placebo inhaler
Drug: Placebo
2 caps BID x42 days

Primary Outcome Measures :
  1. To determine the airway specific, and general safety and the tolerability of inhaled TPI 1020 administered via Aerolizer™ in COPD patients. • To assess the effects of TPI 1020 versus those of budesonide on sputum neutrophil counts on Days 0 and 42. [ Time Frame: 42 days ]

Secondary Outcome Measures :
  1. Sputum neutrophil counts on Days 0 and 21. • Trough FEV1, SVC and IC on Days 0, 21 and on Day 42. • eNO levels on Days 0, 21 and on Day 42. [ Time Frame: 42 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients, male or female, smoker or ex-smoker (who quit at least a year ago) with a smoking history equal or greater than 10 pack years.
  • Age between 40 and 80 years old with a diagnosis (for at least 12 months) of mild to moderate COPD

Exclusion Criteria:

  • COPD exacerbations indicated by a treatment with oral or systemic glucocorticosteroids and/or hospitalization and/or clinically relevant respiratory infection requiring antibiotics within 3 month of the start of the study.
  • Failure to produce a sufficient sputum sample during the screening sputum induction procedure, required for TCC and differential cell count determination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00483743

Layout table for location information
Canada, Alberta
University of alberta Hsopital
Edmonton, Alberta, Canada, T6G2B7
Canada, British Columbia
Vancouver Hospital Lung Center
Vancouver, British Columbia, Canada, V5Z 1 M9
Canada, Ontario
Firestone Institute for Respiratory Health
Hamilton, Ontario, Canada, L8N4A6
Canada, Quebec
Clinique Medical Les Saules
Les Saules, Quebec, Canada, G1P 1J6
Omnispec Clinical Research Inc.
Mirabel, Quebec, Canada, J7J 2K8
Hopital Thoracique Montreal-CSUM
Montreal, Quebec, Canada, H2X2P4
Hopital Sacre Coeur de Montreal
Montreal, Quebec, Canada, H4J1C5
Kells Medical Research Group
Pointe-Claire, Quebec, Canada, H9R 4S3
Diex Research Inc.
Sherbrooke, Quebec, Canada, J1H 1Z1
Sherbrooke, Quebec, Canada, J1H5N4
Complexe Medicale Langelier
St-Leonard, Quebec, Canada, H1S 3A9
Centre de Cardiologie et de Pneumologie de l'Université Laval
Ste-Foy, Quebec, Canada, G1V 4G5
Canada, Saskatchewan
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Francois Maltais, MD Centre de Cardiologie et de Pneumologie de l'Université Laval
Study Director: Rene Pageau, M.Sc Pharm Pharmaxis

Layout table for additonal information
Responsible Party: Pharmaxis Identifier: NCT00483743    
Other Study ID Numbers: TPI 1020-203
First Posted: June 7, 2007    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists